COMPLETE IF KNOWN Substitute for form 1449A/PTO INFORMATION DISCLOSURE Application Number 10/554.001 Filing Date October 21, 2005 STATEMENT BY APPLICANT First Named Inventor Mark T. Bilodeau To be determined 1625 Group Art Unit (use as many sheets as necessary) Examiner Name To be determined-1 of 2 Sheet Attorney Docket Number 21299YP

Examiner	Cite No.	U.S. Patent Document Kind		Name of Patentee or Applicant	Date of Publication of
Initials*		Number	Code (if known)	of Cited Document	Cited Document MM-DD-YYYY
/CC/		5,686,470		Weier, et al.	11/11/1997
		5,506,219		Robl	04/09/1996
		5,594,011		McDonald, et al.	01/14/1997
		5,585,388		Cosford, et al.	12/17/1996
		2002/0127214		Hemmings	09/12/2002
		6,060,491		Pruitt, et al.	05/09/2000
		2004/0106540		Barnett, et al.	06/03/2004
		2004/0116433		Owens, et al.	06/17/2004
		2004/0122012		Owens, et al.	06/24/2004
		6,960,584		Carling, et al.	11/01/2005
		2005/0159422		Lindsley, et al.	07/21/2005
		2005/0182256		Duggan, et al.	08/18/2005
		2005/0222155	1	Bilodeau, et al.	10/06/2005
		2005/0130977		Lindsley, et al.	06/16/2005
		2004/0102360		Barnett, et al.	05/27/2004
/CC/		2005/0288294		Duggan, et al.	12/29/2005

	FOREIGN PATENT DOCUMENTS							
Examin Initials	٠	Cite No.	Foreign Patent Document Office Number Kind Code (if known)		Name of Patentee or Applicant of Cited Document		Date of Publication of Cited Document MM-DD-YYYY	
/CC	7		EP	0356788		E.R Squibb & Sons, Inc.		03/07/1990
	Т		PCT	WO 96/15123		The Salk Institute Biotechnolo	gy	05/23/1996
	Т		PCT	WO 96/24584		G.D Searle & Company		08/15/1996
	Т		PCT	WO 96/31475		Sibia Neurosciences, Inc.		10/10/1996
	T		PCT	WO 97/22360		Medical Research Counsil		06/26/1997
П	Т		PCT	WO 01/91754		Peptor Ltd.		12/06/2001
П	T		PCT	WO 96/23769		Smithkline Beecham PLC.		08/08/1996
П	T		PCT	WO 02/083138		Merck & Co., Inc.		10/24/2002
/CC/			PCT	WO 03/084473		Merck & Co., Inc.		10/16/2003
<u></u>	\perp							
Exam				/Celia Chang/		Date Considered	7/11	/2008

Signature / O-Elid O'Hally Considered / Include Considered / Include Considered / Include Copy of this form with next remandaction to applican.

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (07-05). Information Disclosure Statement by Applicant

					Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE	
Su	hstitute for form 1449B/PTO			COMPLETE IF KNOWN		
INFORMATION DISCLOSURE				Application Number	10/554,001	
STATEMENT BY APPLICANT			DI ICANIT	Filing Date	October 21, 2005	
3	IAIEMENIDI	AP	PLICANI	First Named Inventor	Mark T. Bilodeau	
				Group Art Unit	To be determined	
	(use as many sheets as necessary)			Examiner Name	To be determined	
Sheet	2	of	2	Attorney Docket Number	21299YP	

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/CC/		Bilodeau, et al. Database on Stn. No. 139:350754, WO 2003/086394
		Barnett, et al. Database on Stn. No. 139:323527, WO 2003/084473 (203)
		Zhao, et al. Biorganic & Medicinal Chemistry Letters, Vol. 15 (4), pp. 905-909, Database o Stn. No. 142:211437 (2005)
		DeFeo-Jones, et al. Molecular Cancer Therapeutics, Vol. 4(2), pg. 271-279 (2005)
/CC/		Lindsley, et al. Bioorganic & Medicinal Chemistry Letters, Vol. 15(3), pg. 761-764 (2005)
-		

Examiner Signature /Celia Chang/ Date Cons	sidered 7/11/2008
--	-------------------